CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes

ConditionPreDiabetes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorState University of New York at Buffalo

About this trial

Prediabetes affects over one-third of adults in the United States, placing them at a higher risk for developing type 2 diabetes and heart disease, which can lead to serious health complications and increased medical costs. Although a program called the Diabetes Prevention Program (DPP) has been shown to lower the risk of diabetes through healthy lifestyle changes, many people find it difficult to stick with these changes over the long term. This study seeks to find out if combining DPP coaching with continuous glucose monitoring (CGM) technology can help people stay on track with their health goals.

Eligibility criteria

Qualifiers

adults aged 18 years or older,

diagnosis of prediabetes, as defined by current clinical guidelines (HbA1c 5.7% to 6.4%, fasting plasma glucose 100-125 mg/dL, or 2-hour plasma glucose 140-199 mg/dL following a 75g oral glucose tolerance test),

body mass index (BMI) of at least 24 kg/m² (or 22 kg/m² for Asian Americans),

willingness to comply with all aspects of the study protocol, including attending coaching sessions and using CGM devices.

Disqualifiers

have a diagnosis of type 1 or type 2 diabetes,

are currently using CGMs or have medical contraindications to CGM use, such as severe skin allergies or implantable defibrillators, or

are currently enrolled in another clinical trial for prediabetes. Additionally, using validated assessments, we will exclude participants with significant dementia, alcohol or drug abuse/dependency, active psychosis, or life expectancy less than 12 months as these conditions are likely to interfere with adherence to the intervention.

Trial design

Treatments tested in this trial

  • CGM-DPP
  • Control

Treatment groups

214 Participants
are divided into 2 treatment groups